Archive: News
-
Dr. Marshall Discusses the State of RAS Mutations in GI Cancers
John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses the current state of RAS-mutant gastrointestinal (GI) cancers during the 2017 Ruesch Center Symposium.
Category: News
-
Luminary Awards Reignite Commitment to Ending GI Cancers
Five leaders in the fight against gastrointestinal (GI) cancers from academia, the community, and clinic were honored last night at the inaugural Luminary Awards.
Category: News
-
Dr. Marshall on the Luminary Awards in GI Cancers
John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses the first annual Luminary Awards in GI Cancers, which is honoring five individuals who have devoted their time, talent and resources to improving the care for patients and families affected by GI cancers.
Category: News
-
Dr. Henry Lynch to be honored again for his cancer research
In December, Dr. Henry Lynch will be honored again for his work by the Ruesch Center for the Cure of Gastrointestinal Cancers at Georgetown Lombardi Comprehensive Cancer Center in Washington, D.C.
Category: News
-
Genomic Profiling Identifies Patients Most Likely to Respond to Immunotherapy
New discoveries and ongoing research continue to confirm the powerful therapeutic implications of precision medicine for cancer patients. The recent FDA approval of pembrolizumab for patients whose cancers have a specific biomarker is no exception.
Category: News
-
Tumor Mutations: The Upside?
A team of investigators led by researchers at Georgetown Lombardi Comprehensive Cancer Center has found that the tumor mutation load (TML) in a patient’s cancer biopsy varied by age and the type of cancer, along with several other factors. The findings include 14 types of solid tumors and over 8,000 tissue samples, offering one of the most comprehensive analyses of TML to date.
Category: News
-
Deficiencies in DNA Repairing Identified in Tumors
The DNA repair deficiency, called homologous recombination deficiency, or HRD, has previously been studied in only a few cancers, but as researchers at Georgetown Lombardi Comprehensive Cancer Center report, HRD can be found in all of the cancer types the researchers studied, including prostate, breast, pancreatic, and endometrial cancers as well as two of the more deadly types: ovarian cancer and glioma, a type of brain cancer.
Category: News
-
Ultra-personal therapy: Gene tumor boards guide cancer care
Doctors were just guessing a decade ago when they gave Alison Cairnes’ husband a new drug they hoped would shrink his lung tumors. Now she takes it too, but the choice was no guesswork. Sophisticated gene tests suggested it would fight her gastric cancer, and they were right.
Category: News
-
Time to Change the Way We Price Drugs: Value-based pricing, technology assessment among possible solutions
The U.S. should develop a different system of pricing drugs, Peter Bach, MD, said at a forum in Washington, DC on high prescription drug prices hosted by The Atlantic.
Category: News
-
Young Adults Face Steep Increase of Colorectal Cancer Risk
New study shows increased risk of colorectal cancer among young adults as risk among older adults declines.
Category: News